EnteroBiotix
Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.
About
EnteroBiotix is a clinical-stage microbiome therapeutics company focused on transforming the standard of care for patients with gastrointestinal disease. Their lead investigational product, EBX-102-02, is an orally delivered, full-spectrum microbiome drug in clinical development for irritable bowel syndrome (IBS) and other gastrointestinal and liver-related diseases. EBX-102-02 is a high-diversity microbial product manufactured using proprietary AMPLA™ drying technology. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does EnteroBiotix do?
EnteroBiotix is a Biotechnology company that offers Biotechnology. Teams look it up for Pharmaceuticals, Healthcare, Life Sciences. It is based in Glasgow, United Kingdom and was founded in 2017. Public records show $41M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $41M in funding. The most recent round on record is Funding Round.
Where is EnteroBiotix headquartered?
EnteroBiotix is headquartered in Glasgow, United Kingdom.
When was EnteroBiotix founded?
EnteroBiotix was founded in 2017.
What industry does EnteroBiotix operate in?
EnteroBiotix operates in Biotechnology, Pharmaceuticals, Healthcare, Life Sciences, Microbiome.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.